Ranbaxy Laboratories, a division of Daiichi Sankyo Company, and EPIRUS Switzerland GmbH, a wholly-owned subsidiary of Boston-based EPIRUS Biopharmaceuticals, Inc., have inked a licensing agreement for BOW015, a biosimilar version of Infliximab. The product will be introduced in India and other Emerging Markets. Currently, there is no biosimilar of Infliximab approved in India.
Under the terms of the agreement, EPIRUS will develop and supply the product, and upon regulatory approval Ranbaxy will market the same in India and other emerging markets. BOW015 is a biosimilar version of infliximab, a biologic therapy marketed under the name REMICADE.
Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
Under the terms of the agreement, EPIRUS will develop and supply the product, and upon regulatory approval Ranbaxy will market the same in India and other emerging markets. BOW015 is a biosimilar version of infliximab, a biologic therapy marketed under the name REMICADE.
Ranbaxy Laboratories, India’s largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.
No comments:
Post a Comment